Sage Journals: Discover world-class research

Retricted access

Review article

First published 2025

Lutetium Lu 177 vipivotide tetraxetan: A literature review

Grace Morrison, Lisa M Holle

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2003-10

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2011-06

Preparation of Patient Doses of 177 Lu-DOTA-TATE Using Indigenously Produced 177 Lu: The Indian Experience

Tapas Das, Sudipta Chakraborty, Kumar G. Kallur [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2007-06

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177 Lu DOTA-TATE and 177 Lu DOTA-NOC

Christiane Wehrmann, Stefan Senftleben, Carolin Zachert [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2022-04

Estimation of Absorbed Doses of Indigenously Produced “Direct-route” Lutetium-177-[ 177 Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [ 177 Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles

Kamaldeep, Gaurav Wanage, Sarvesh Loharkar [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2003-04

Three-Dimensional Dose Model for the Comparison of 177 Lu-HuCC49ΔCH2 and 177 Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts

Peter L. Roberson, Shigeru Yokoyama, Buck E. Rogers [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 1957-8

Effect of Specific Activity on Distribution of Radiolutecium (Lu 177 ). ∗

William M. Christopherson, Granvil C. Kyker, H. F. Berg [...]

Experimental Biology and Medicine

Retricted access

Research article

First published 2025-04

Generalized Seizure as an Acute post-[ 177 Lu]Lu-DOTATATE Side Effect in a Case of Recurrent Meningioma

Abdolmajid Alipour, Tahereh Ghaedian, Abbas Rakhsha [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2022-06

Clinical Dose Preparation of [ 177 Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177 Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers,with HER2 Receptor Overexpression

Sreeja Raj Menon, Arpit Mitra, Avik Chakraborty [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2020-04

Comparative In Vitro Cytotoxicity Studies of 177 Lu-CHX-A″-DTPA-Trastuzumab and 177 Lu-CHX-A″-DTPA-F(ab′) 2 -Trastuzumab in HER2-Positive Cancer Cell Lines

Rohit Sharma, Mythili Kameswaran, Ashutosh Dash

Cancer Biotherapy and Radiopharmaceuticals

Search results